<DOC>
	<DOCNO>NCT02540395</DOCNO>
	<brief_summary>The main objective study demonstrate utility safety IFN-γ ( Interferon Gamma ) ELISPOT ( Enzyme-linked immunosorbent spot ) marker stratification kidney transplant recipient low high IS ( Immunosuppression ) regimens . The enrichment study test non-inferiority low IS regimen compare high IS regimen , assume 10 % BPAR 6-months control group , allow non-inferiority limit maximum 10 % .</brief_summary>
	<brief_title>Prospective Donor Specific T Response Measurment IS Minimization de Novo Renal Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Men woman , age ≥18 year . 2 . Subject must recipient first renal transplant decease live donor . 3 . Subject must current document PRA ( Panel reactive antibody ) &lt; 20 % detectable anticlass I II HLA ( human leukocyte Antigens ) antibodies solid phase assay ( Luminex® ) . 4 . Subject willing provide sign write informed consent . 5 . Women Childbearing Potential ( WOCBP ) must use highly effective method contraception ( PearlIndex &lt; 1 ) avoid pregnancy throughout study manner risk pregnancy minimize . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal [ define amenorrhea ≥ 12 consecutive month ; woman hormone replacement therapy ( HRT ) document serum follicle stimulate hormone ( FSH ) level &gt; 35 mIU/mL ] . WOCBP must negative serum urine pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ( Human chorionic gonadotropin ) ) within 72 hour prior start clinical trial . 1 . Subjects undergo renal transplant current document PRA &gt; 20 % and/or detectable anticlass I II HLA antibody solid phase assay ( Luminex® ) . 2 . CDC ( complement dependent cytotoxicity ) positive cross match . 3 . Subjects receive allograft donor old 65 year elevate creatinine level and/or treat diabetes . 4 . Cold ischemia time ( CIT ) high 24h . 5 . Subjects prior solid organ transplant ( SOT ) , include renal retransplantation , receive concurrent SOT . 6 . Patients previously treat daclizumab basiliximab . 7 . Subjects underlie renal disease : Primary focal segmental glomerulosclerosis . Type I II membranoproliferative glomerulonephritis Atypical Haemolytic uremic syndrome ( HUS ) / thrombotic thrombocytopenic purpura syndrome . 8 . Subject Hepatitis B chronic infection and/or active infection Hepatitis C virus ( positive PCR ( polymerase chain reaction result ) moment transplant . 9 . Subjects know human immunodeficiency virus ( HIV ) infection . 10 . Patients active systemic infection require continue use antibiotic . 11 . Patients neoplasia except localized skin cancer receive appropriate treatment . 12 . Patients severe anemia ( hemoglobin &lt; 6g/dl ) , leucopenia ( WBC ( White blood cell ) &lt; 2500/mm3 ) , thrombocytopenia ( platelet &lt; 80.000/mm3 ) . 13 . Hemodynamically instable patient even hemoglobin level count &gt; 6 g/dl . 14 . Patients intestinal pathology severe diarrhoea hinder absorption accord medical criterion . 15 . Subjects know hypersensibility drug use protocol . 16 . Subjects use investigational drug within 30 day prior enrolment clinical trial . 17 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period , woman pregnant breastfeed woman positive pregnancy test enrolment . 18 . Subjects legally detain official institution</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Kidney transplantation</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>IFN-γ</keyword>
</DOC>